OliX PharmaceuticalsInc (226950) — Cash Flow-to-Debt Ratio
OliX PharmaceuticalsInc (226950) has a Cash Flow-to-Debt Ratio of -0.27x as of December 2025, meaning its operating cash flow of ₩-12.16 Billion could theoretically repay 0% of its total liabilities (₩45.29 Billion) in one year. See how much free cash does OliX PharmaceuticalsInc generate to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
OliX PharmaceuticalsInc Cash Flow-to-Debt Ratio (2016–2025)
Historical debt coverage capacity for OliX PharmaceuticalsInc across 10 annual periods. Also explore how fast is OliX PharmaceuticalsInc growing its equity to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for OliX PharmaceuticalsInc (2016–2025)
Year-by-year debt coverage analysis for OliX PharmaceuticalsInc. For market capitalisation and broader financial context, see market value of OliX PharmaceuticalsInc.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.35x | ₩-15.90 Billion | ₩45.29 Billion | ▲ +33.1% |
| 2024 | -0.53x | ₩-28.04 Billion | ₩53.40 Billion | ▼ -30.2% |
| 2023 | -0.40x | ₩-21.17 Billion | ₩52.49 Billion | ▲ +12.3% |
| 2022 | -0.46x | ₩-30.68 Billion | ₩66.74 Billion | ▼ -64.4% |
| 2021 | -0.28x | ₩-19.05 Billion | ₩68.15 Billion | ▼ -147.6% |
| 2020 | -0.11x | ₩-3.76 Billion | ₩33.29 Billion | ▲ +96.4% |
| 2019 | -3.15x | ₩-10.73 Billion | ₩3.41 Billion | ▲ +73.7% |
| 2018 | -11.96x | ₩-8.36 Billion | ₩698.94 Million | ▼ -640.5% |
| 2017 | -1.62x | ₩-4.79 Billion | ₩2.96 Billion | ▼ -21.4% |
| 2016 | -1.33x | ₩-3.45 Billion | ₩2.59 Billion | — |